ATE499104T1 - Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns - Google Patents

Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns

Info

Publication number
ATE499104T1
ATE499104T1 AT08167618T AT08167618T ATE499104T1 AT E499104 T1 ATE499104 T1 AT E499104T1 AT 08167618 T AT08167618 T AT 08167618T AT 08167618 T AT08167618 T AT 08167618T AT E499104 T1 ATE499104 T1 AT E499104T1
Authority
AT
Austria
Prior art keywords
brain
treatment
traumatic injury
nervous system
central nervous
Prior art date
Application number
AT08167618T
Other languages
English (en)
Inventor
Stuart W Hoffman
Arthur L Kellerman
Donald G Stein
David W Wright
Douglas W Lowery-North
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE499104T1 publication Critical patent/ATE499104T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AT08167618T 2005-03-24 2006-03-24 Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns ATE499104T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66472805P 2005-03-24 2005-03-24
US72966305P 2005-10-24 2005-10-24

Publications (1)

Publication Number Publication Date
ATE499104T1 true ATE499104T1 (de) 2011-03-15

Family

ID=36987966

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06739662T ATE520404T1 (de) 2005-03-24 2006-03-24 Verfahren zur behandlung einer verletzung des zentralen nervensystems durch ausschleichende verabreichung von progesteron
AT08167618T ATE499104T1 (de) 2005-03-24 2006-03-24 Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06739662T ATE520404T1 (de) 2005-03-24 2006-03-24 Verfahren zur behandlung einer verletzung des zentralen nervensystems durch ausschleichende verabreichung von progesteron

Country Status (16)

Country Link
US (4) US20090221544A1 (de)
EP (5) EP1871382B1 (de)
JP (5) JP5295755B2 (de)
AT (2) ATE520404T1 (de)
AU (2) AU2006226811B2 (de)
CA (2) CA2601715C (de)
CY (2) CY1111478T1 (de)
DE (1) DE602006020353D1 (de)
DK (2) DK1868614T3 (de)
ES (2) ES2428313T3 (de)
HK (3) HK1112579A1 (de)
HR (2) HRP20110198T1 (de)
PL (2) PL1868614T3 (de)
PT (2) PT2030622E (de)
RS (1) RS52471B (de)
WO (2) WO2006102596A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
ES2428313T3 (es) 2005-03-24 2013-11-07 Emory University Métodos para el tratamiento de lesiones del sistema nervioso central mediante un protocolo de administración decreciente
EP2052724A1 (de) * 2007-10-26 2009-04-29 sanofi-aventis Verwendung von Norgestimat als selektivem Hemmer der Ionenkanäle TRPC3, TRPC6 sowie TRPC6 und TRPC7
EP2260052A4 (de) 2008-02-26 2013-01-16 Univ Emory Steroidanaloga für neuroprotektion
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
WO2010088409A2 (en) * 2009-01-30 2010-08-05 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
EP3689364A1 (de) 2010-02-08 2020-08-05 Shenzhen Evergreen Therapeutics Co., Ltd. Verfahren zur verwendung von progestogen als glucocorticoid-sensibilisierer
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
CA2834286A1 (en) * 2011-04-27 2012-11-01 Northwestern University Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
BR112014018110B1 (pt) * 2012-01-23 2022-06-07 Sage Therapeutics, Inc Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina
US20130210785A1 (en) 2012-02-15 2013-08-15 Emory University Progesterone analogs and uses related thereto
EP2819650A1 (de) 2012-02-29 2015-01-07 B. Braun Melsungen AG Hormonhaltige emulsion mit krillphospholipiden
RU2498826C1 (ru) * 2012-05-14 2013-11-20 Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук Способ лечения больных с черепно-мозговой травмой
EP2887944B1 (de) * 2012-08-21 2021-10-06 Sage Therapeutics, Inc. Allopregnanolon zur behandlung von refraktärem status epilepticus
CA2892811A1 (en) 2012-11-30 2014-06-05 The Regents Of The University Of California Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression
BR112015018092A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
WO2014120800A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
LT3514158T (lt) 2013-01-29 2023-02-10 Aptinyx Inc. Spirolaktaminiai nmda receptoriaus moduliatoriai ir jų panaudojimas
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
EA032153B1 (ru) 2013-01-29 2019-04-30 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
DK3033350T3 (da) 2013-08-12 2021-08-30 Univ Emory Progesterone fosfatanaloger og anvendelser relateret dertil
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
EP3426257A4 (de) 2016-03-08 2019-11-13 Sage Therapeutics, Inc. Neuroaktive steroide, zusammensetzungen und verwendungen davon
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2018014202A (es) 2016-05-19 2019-06-20 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
BR112019001923A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores de nmda de espiro-lactama e métodos de sua utilização
AU2017305240B2 (en) 2016-08-01 2021-12-09 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
AU2017306152A1 (en) 2016-08-01 2019-01-31 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
PE20190500A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y uso de los mismos
MX2019001322A (es) 2016-08-01 2019-09-11 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
JP7210599B2 (ja) 2018-01-31 2023-01-23 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
WO2020180424A1 (en) 2019-03-04 2020-09-10 Iocurrents, Inc. Data compression and communication using machine learning
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
US20230190709A1 (en) * 2021-12-02 2023-06-22 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217085A (en) 1975-07-30 1977-02-08 Ono Pharmaceut Co Ltd Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes
US4404366A (en) * 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4369250A (en) 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
USRE35517E (en) * 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
AU609927B2 (en) 1987-08-25 1991-05-09 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5512429A (en) 1989-09-19 1996-04-30 British Technology Group Limited Assay for enzyme activity
GB9105707D0 (en) 1991-03-18 1991-05-01 Wilton David C Assay
US5114388A (en) * 1991-07-26 1992-05-19 True Fitness Technology, Inc. Stair simulator exerciser with adjustable incline
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
AU5855794A (en) * 1993-01-19 1994-08-15 Endorecherche Inc. Therapeutic uses and delivery systems of dehydroepiandrosterone
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
WO1995005826A1 (en) * 1993-08-20 1995-03-02 Jackson Meyer B Method for regulating neuropeptide hormone secretion
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US5741899A (en) * 1995-02-02 1998-04-21 Cell Genesys, Inc. Chimeric receptors comprising janus kinase for regulating cellular pro liferation
DE69634039T2 (de) * 1995-06-06 2005-12-08 Euro-Celtique S.A. Steroidderivate der Androstan- und der Pregnanreihe
US5942241A (en) * 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
AU3136897A (en) 1996-05-22 1997-12-09 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
DE69809223T2 (de) 1997-05-02 2003-07-24 Wyeth Corp 5-alpha-pregnan-3-beta-ol-20-one 3-sulfate für di behandlung von tumoren und zns krankheiten
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6268223B1 (en) 1999-08-27 2001-07-31 Viatech Imagin, Llc Assay for detecting damage to the central nervous system
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
ES2428313T3 (es) * 2005-03-24 2013-11-07 Emory University Métodos para el tratamiento de lesiones del sistema nervioso central mediante un protocolo de administración decreciente

Also Published As

Publication number Publication date
US20090221544A1 (en) 2009-09-03
PL2030622T3 (pl) 2011-07-29
HK1128242A1 (en) 2009-10-23
DE602006020353D1 (de) 2011-04-07
JP2014055183A (ja) 2014-03-27
WO2006102644A9 (en) 2006-11-23
HK1112579A1 (en) 2008-09-12
EP1871382A2 (de) 2008-01-02
ES2392454T3 (es) 2012-12-10
EP1868614B1 (de) 2012-08-08
JP2011225629A (ja) 2011-11-10
US20090325920A1 (en) 2009-12-31
PT2030622E (pt) 2011-06-02
WO2006102596A3 (en) 2007-01-18
ATE520404T1 (de) 2011-09-15
AU2006226811A1 (en) 2006-09-28
CY1111478T1 (el) 2015-08-05
DK2030622T3 (da) 2011-05-02
PT1868614E (pt) 2012-11-23
HRP20110198T1 (hr) 2011-04-30
WO2006102644A3 (en) 2007-03-01
EP2431042B1 (de) 2013-06-26
WO2006102596A2 (en) 2006-09-28
CY1113253T1 (el) 2016-04-13
US8614203B2 (en) 2013-12-24
CA2602950A1 (en) 2006-09-28
JP5394059B2 (ja) 2014-01-22
CA2601715A1 (en) 2006-09-28
DK1868614T3 (da) 2012-11-12
JP5496407B2 (ja) 2014-05-21
JP2008534512A (ja) 2008-08-28
AU2006226774A1 (en) 2006-09-28
HRP20120688T1 (hr) 2012-09-30
EP2030622A1 (de) 2009-03-04
US20120289491A1 (en) 2012-11-15
CA2601715C (en) 2012-10-16
JP2013234191A (ja) 2013-11-21
EP2431042A1 (de) 2012-03-21
WO2006102644A2 (en) 2006-09-28
ES2428313T3 (es) 2013-11-07
HK1112581A1 (en) 2008-09-12
EP1871382B1 (de) 2011-08-17
AU2006226811B2 (en) 2010-11-25
RS52471B (en) 2013-02-28
EP1868614A2 (de) 2007-12-26
EP2494976A1 (de) 2012-09-05
EP2030622B1 (de) 2011-02-23
PL1868614T3 (pl) 2013-01-31
JP5295755B2 (ja) 2013-09-18
AU2006226774B2 (en) 2010-12-02
CA2602950C (en) 2012-10-30
US20120245133A1 (en) 2012-09-27
JP2008534515A (ja) 2008-08-28

Similar Documents

Publication Publication Date Title
ATE499104T1 (de) Progesterone dosierungsanweisung in der behandlung einer traumatischen verletzung des gehirns
PH12019502254A1 (en) Methods and systems for modulating stimuli to the brain with biosensors
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
EA201590870A1 (ru) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ
WO2017190044A8 (en) Methods for detecting and treating pain using brain activity
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
RU2013122987A (ru) Способ лечения комбинированного радиационно-термического поражения
ATE485819T1 (de) Benzamidin derivative zur behandlung und vorbeugung von mucositis
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
ATE380554T1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
EP2566856A4 (de) Verbindungen und verfahren zur behandlung von hirnerkrankungen
WO2009111681A3 (en) Gallium compounds and methods of use to treat inflammatory bowel disease
WO2014201084A3 (en) Piroxicam transdermal composition to treat plantar fasciitis
MX2015013137A (es) Compuestos novedosos de modulación del control de la respiración, y sus métodos de uso.
WO2011071981A3 (en) Anti-cytomegalovirus activity of artemisinin-derived dimers
WO2006096458A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2015051279A3 (en) Cxcr4 up- and down-regulation for treatment of diseases or disorders
김유찬 DonSymposium 2-2-2 (SYP 2-2-2): Intensified photodynamic therapy
Osiecka Diclofenac/tazarotene
Greveling Atopic contact dermatitis: case report
MX2016002655A (es) Metodo para reducir la muerte de celulas neuronales con haloalquilaminas.
Khasanova et al. The use of tizanidine in combined treatment of arm poststroke spasticity

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2030622

Country of ref document: EP